Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03004183 · ClinicalTrials.gov registry record · Phase 2
SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
A Phase 2 study, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT03004183 is a Phase 2 study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 57 participants.
The verdict
NCT03004183, a Phase 2 study, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
This is a Phase II trial to determine the efficacy and safety of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy used as a window of opportunity treatment before pembrolizumab in patients with metastatic triple negative breast cancer (TNBC) and metastatic non-small cell lung cancer (NSCLC). In situ oncolytic virus therapy will consist of adenovirus-mediated expression of herpes simplex virus thymidine kinase (ADV/HSV-tk) plus valacyclovir therapy.
Interventions
- DRUG Pembrolizumab
- RADIATION SBRT
- DRUG Valacyclovir
- BIOLOGICAL ADV/HSV-tk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2024-01-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03004183
The ClinicalTrials.gov registry entry for NCT03004183 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03004183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03004183 about?
NCT03004183 is a clinical study titled "SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC". This is a Phase II trial to determine the efficacy and safety of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy used as a window of opportunity treatment before pembrolizumab in patients with metastatic triple negative breast cancer (TNBC) and metastatic non-small cel...
What is the current status of trial NCT03004183?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2017-07-01. Estimated completion is 2024-01-09.
What interventions are being tested in trial NCT03004183?
The interventions under investigation include: Pembrolizumab (DRUG), SBRT (RADIATION), Valacyclovir (DRUG), ADV/HSV-tk (BIOLOGICAL).
Who is sponsoring clinical trial NCT03004183?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.